Physician profile
Robert N Smith
NPI 1891746350
$1,245.58
in general payments reported to CMS, 2019-2025
20 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $107 · 2022: $12.10 · 2023: $19.04 · 2024: $364 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $149.51 | 2019-2024 | Veltassa |
| Astrazeneca Pharmaceuticals Lp | $141.16 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.06 | 2023-2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $125.55 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $81.09 | 2019-2024 | Jynarque |
| Amgen INC. | $77.64 | 2019-2025 | Tavneos |
| Calliditas Therapeutics US INC. | $77.32 | 2024-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $75.88 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $67.07 | 2024-2025 | |
| Travere Therapeutics, INC. | $55.86 | 2019-2020 | |
| Amicus Therapeutics, INC. | $53.89 | 2019-2020 | |
| Horizon Therapeutics Plc | $37.23 | 2019-2022 | |
| Akebia Therapeutics INC | $35.71 | 2019 | |
| Genentech USA, INC. | $29.78 | 2025 | Gazyva |
| Baxter Healthcare | $25.92 | 2024 | Renal - Pd |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $23.32 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.03 | 2024 | Xarelto |
| Novo Nordisk INC | $16.58 | 2025 | Ozempic |
| Opko Pharmaceuticals, LLC | $14.92 | 2019 | |
| Shire North American Group INC | $14.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.